Estrogen receptor pathways in lung cancer

Kuiper GG, Enmark E, Pelto-Huikko M, et al.: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996, 93:5925–5930.

Mosselman S, Polman J, Dijkema R: ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996, 392:49–53.

Enmark E, Pelto-Huikko M, Grandien K, et al.: Human estrogen receptor b-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997, 82:4258–4265.

Castelao JE, Yuan J-M, Skipper PL, et al.: Gender- and smokingrelated bladder cancer risk. J Natl Cancer Inst 2001, 93:538–545.

Reynolds P, Hurley S, Goldberg DE, et al.: Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst 2004, 96:29–37.

Muscat JE, Richie JP, Thompson S, Wynder EL: Gender differences in smoking and risk for oral cancer. Cancer Res 1996, 56:5192–5197.

Ahsan H, Neugut AI, Gammon MD: Association of adenocarcinoma and squamous cell carcinoma of the esophagus with tobacco-related and other malignancies. Cancer Epidemiol Biomarkers Prev 1997, 6:779–782.

National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program. http://www.seer.cancer.gov. Accessed January 7, 2004.

American Cancer Society Surveillance Research: Cancer facts and figures 2002; Atlanta, GA: American Cancer Society; 2002:1–43.

United States Department of Health and Human Services: Women and smoking: a report of the Surgeon General-2001. http://www.surgeongeneral.gov/library. Accessed January 7, 2004.

Lienert T, Serke M, Schonfeld N, Loddenkemper R: Lung cancer in young females. Eur Respir J 2000, 16:986–990.

Achievements in Public Health, 1900–1999. Tobacco use: United States, 1900–1999. MMWR Morb Mortal Wkly Rep 1999, 48:986–993.

State-specific prevalence among adults of current cigarette smoking and smokeless tobacco use and per capita tax-paid sales of cigarettes: United States, 1997. MMWR Morb Mortal Wkly Rep 1998, 47:922–926.

Zang EA, Wynder EL: Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996, 88:183–192.

Wynder EL: The past, present and future of the prevention of lung cancer. Cancer Epidemiol Biomarkers Prev 1998, 7:735–748.

Sorensen G, Pechacek TF: Attitudes toward smoking cessation among men and women. J Behav Med 1987, 10:129–137.

Westmaas JL, Wild TC, Ferrence R: Effects of gender in social control of smoking cessation. Health Psychol 2002, 21:368–376.

Women and smoking: a national state-by-state report card. National Women’s Law Center. Oregon Health and Science University 2003. http://www.nwlc.org/pdf/Women&Smoking-ReportCard2003.pdf. Accessed January 15, 2004.

Baldini EH, Strauss GM: Women and lung cancer: waiting to exhale. Chest 1997, 124:229S-234S.

Ferguson MK, Skosey C, Hoffman PC, Golumb HM: Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 1990, 8:1402–1407.

Siegfried JM: Women and lung cancer: Does oestrogen play a role? Lancet Oncol 2001, 2:506–513.

Mennecier B, Lebitasy M-P, Moreau L, et al.: Women and small cell lung cancer: social characteristics, medical history, management and survival: a retrospective study of all the male and female cases diagnosed in Bas-Rhin (Eastern France) between 1981 and 1994. Lung Cancer 2003, 42:141–152.

Henschke CI, Miettinen OS: Women’s susceptibility to tobacco carcinogens. Lung Cancer 2004, 43:1–5. This report addresses the absolute risk for lung cancer in women who smoke relative to that of men who smoke an equal amount.

Halpern MT, Billespie BW, Warner KE: Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993, 85:457–464.

Kreuzer M, Boffetta P, Whitley E, et al.: Gender differences in lung cancer risk by smoking: a multicentre case-control study in Germany and Italy. Br J Cancer 2000, 82:227–233.

Sellers TA, Potter JD, Bailey-Wilson JE, et al.: Lung cancer detection and prevention: evidence for an interaction between smoking and genetic predisposition. Cancer Res 1992, (Suppl):2694S–2697S.

Wang SY, Hu YL, Wu YL, et al.: A comparative study of the risk factors for lung cancer in Guangdong, China. Lung Cancer 1996, 14(Suppl 1):S99-S105.

Cannon-Albright LA, Thomas A, Goldgar DE, et al.: Familiality of cancer in Utah. Cancer Res 1994, 54:2378–2385.

Schwartz AG, Yang P, Swanson GM: Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 1996, 144:554–562.

Dresler CM, Fratelli C, Babb J, et al.: Gender differences in genetic susceptibility for lung cancer. Lung Cancer 2000, 30:153–160.

Wei Q, Cheng L, Amos CL, et al.: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiology study. J Natl Canc Inst 2000, 92:1764–1772.

Nelson HH, Christiani DC, Mark EJ, et al.: Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999, 91:2032–2038.

Guinee DG Jr, Travis WD, Trivers GE, et al.: Gender comparisons in human lung cancer: analysis of p53 mutations, antip53 serum antibodies and C-erbB-2 expression. Carcinogenesis 1995, 16:993–1002.

Kure EH, Ryberg D, Hewer A, et al.: p53 mutations in lung tumors: relationship to gender and lung DNA adduct levels. Carcinogenesis 1996, 17:2201–2205.

Shriver BP, Bourdeau HA, Gubish CT, et al.: Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst 2000, 92:24–33.

Dreyer L, Prescott E, Gyntelberg F: Association between atherosclerosis and female lung cancer: a Danish cohort study. Lung Cancer 2003, 42:247–254.

Henderson BE, Ross RK, Pike MC, Casagrande JT: Endogenous hormones as a major factor in human cancer. Cancer Res 1982, 42:3232–3239.

Taioli E, Wynder EL: Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994, 86:859–870.

Jiang YG, Chen JK, Wu ZL: Promotive effect of diethylstilbestrol on urethan-induced mouse lung tumorigenesis. Chemospere 2000, 41:187–190.

Thomsen JS, Wang X, Hines RN, Safe S: Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor. Carcinogenesis 1994, 15:933–937.

Yager JD, Liehr JG: Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996, 36:203–232.

Fishman J: Biological action of catechol oestrogens. J Endocrinol 1981, 89(Suppl):59p-65p.

Matsuda S, Kadowaki Y, Ichino M, et al.: 17 beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product. Proc Natl Acad Sci U S A 1993, 90:10803–10807.

Stabile LP, Gaither Davis AL, Gubish CT, et al.: Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002, 62:2141–2150. This study demonstrates the presence of mainly ERâ in lung cancer cell lines, normal lung fibroblast cell lines, and tumor tissues and shows a functional response to estrogens in the lung.

deJong PC, Blankenstein MA, Nortier JWR, et al.: The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease. J Steroid Biochem Mol Biol 2003, 87:149–155.

Tiutiunova AM, Chirvana ED, Mironenko TV, et al.: Hormonal balance in women with lung cancer and its changes after combined treatment. Vopr Onkol 1986, 32:2–30.

Njar VCO, Brodie AMH: Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 1999, 58:233–255.

Martel C, Melner MH, Gagne D, et al.: Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteriod dehydrogenase/ delta 5-delta 4 isomerase (3 beta-HDS), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 1994, 104:103–111.

Price T, Aiken J, Simpson ER: Relative expression of aromatase cytochrome P450 in human fetal tissues as determined by competitive polymerase chain reaction amplification. J Clin Endocrinol Metab 1992, 74:879–883.

Pettersson K, Gustafsson JA: Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 2001, 63:165–192.

Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF: Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Mol Cell Endo 2000, 162:167–180.

Paech K, Webb P, Kuiper GG, et al.: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277:1508–1510.

Kaiser U, Hofmann J, Schilli M, et al.: Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 1996, 16:3803–3806.

Fasco MJ, Hurteau GJ, Spivack SD: Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002, 188:125–140.

Omoto Y, Kobayashi Y, Nishida K, et al.: Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 2001, 285:340–347. This report demonstrates the importance and functional significance of ERâ in the lung cancer cell lines.

Mollerup S, Jorgensen K, Berge G, Haugen A: Expression of estrogen receptors alpha and beta in human lung tissues and cell lines. Lung Cancer 2002, 37:153–159.

Patrone C, Cassel TN, Pettersson K, et al.: Regulation of postnatal lung development and homeostasis by estrogen receptor b. Mol Cell Biol 2003, 23:8542–8552. This report describes a physiologic role for ERâ in the lung.

Spivack SD, Hurteau GJ, Fasco MJ, Kaminsky LS: Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin Cancer Res 2003, 9:6002–6011.

Roger P, Sahla ME, Makela S, et al.: Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001, 61:2537–2541.

Hall JM, McDonnell DP: The estrogen receptor b-isoform (ERb) of the human estrogen receptor modulates ERa transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999, 140:566–5578.

Moore KA, Mery CM, Jaklitsch MT, et al.: Menopausal effects on presentation, treatment, and survival of women with nonsmall cell lung cancer. Ann Thorac Surg 2003, 76:1789–1795.

Rossing TH, Rossing R: Survival in lung cancer: an analysis of the effects of age, sex, respectability, and histopathologic type. Am Rev Respir Dis 1982, 126:771–777.

Bouchardy C, Fioretta G, DePerrot M, et al.: Determinants of long term survival after surgery for cancer of the lung: a population-based study. Cancer 1999, 86:2229–2237.

Falkenstein E, Wehling M: Nongenomically initiated steroid actions. Eur J Clin Invest 2000, 30(Suppl 3):51–54.

Zhang Z, Maier B, Santen RJ, Song RX: Membrane association of estrogen receptor alpha mediates estrogen effect on MAPK activation. Biochem Biophys Res Commun 2002, 294:926–933.

Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER: ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 2002, 16:100–115.

Figtree GA, McDonald D, Watkins H, Channon KM: Truncated estrogen receptor a 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation 2003, 107:120–126.

Li L, Haynes MP, Bender JR: Plasma membrane localization and function of the estrogen receptor a variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A 2003, 100:480–4812.

Lee AV, Cui X, Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 2001, 7(Suppl):4429s-4435s.

Levin ER: Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003, 17:309–317.

Rajkumar T, Gullick WJ: The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 1994, 29:3–9.

Miettinen PJ, Berger JE, Meneses J, et al.: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376:337–341.

Sibilia M, Wagner EF: Strain dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269:234–238.

Threadgill DW, Dlugosz AA, Hansen LA, et al.: Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995, 269:230–234.

Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991, 47:87–98.

Yarden RI, Wilson MA, Chrysogelos SA: Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem 2001, 36(Suppl):232–246.

Kris MG, Natale RB, Herbst RS, et al.: A phase II trial of ZD1839 (’Iressa’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based chemotherapy regimens (IDEAL 2) [abstract]. Proc ASCO 2002, 21:298a.

Fujiwara K, Kiura K, Ueoka H, et al.: Dramatic effect of ZD1839 (’Iressa’) in a patient with advanced non-small cell lung cancer and poor performance status. Lung Cancer 2003, 40:73–76.

Yano S, Kanematsu T, Miki T, et al.: A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 (’Iressa’). Cancer Sci 2003, 94:453–458.

Giaccone G, Johnson DH, Manegold C, et al.: A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy naÏve patients with advanced nonsmall cell lung cancer (INTACT 1). Ann Oncol 2002, 13:40a.

Johnson DH, Herbst R, Giaccone G, et al.: ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 2002, 13:468a.

Okubo S, Kurebayashi J, Otsuki T, et al.: Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fluvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004, 90:236–244.

Stabile LP, Lyker JS, Gubish CT, Siegfried JM: Targeting the estrogen receptor and the epidermal growth factor receptor for lung cancer therapy. Proc Amer Assoc Cancer Res; 2004, 45:2423.

Hershberger PA, Vasquez AC, Siegfried JM, Nichols MD: Lung cancer cells express estrogen receptor (ER) and coactivators and undergo changes in gene expression in response to ER ligands. Proc Amer Assoc Cancer Res; 2004, 45:289.